Topical cream for early-stage skin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a cream applied to the skin that may help control early-stage mycosis fungoides, a type of skin lymphoma. It aims to see if the cream can reduce symptoms and slow disease progression without the need for stronger treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with mycosis fungoides in stage IA, IB, or IIA.
- Your disease is stable and you need treatment to relieve symptoms.
- You have not changed your lymphoma medications for at least 2 months before the study starts.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use highly effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cream containing duvelisib, a drug that may help treat the skin patches of early-stage mycosis fungoides, a type of skin lymphoma. The cream is applied directly to the affected skin to see if it can control the disease.
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
This study tests a cream called benvitimod to see if it helps treat cutaneous T-cell lymphoma, a type of skin lymphoma. It is for adults who have already been diagnosed with this condition.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This early-stage study tests whether a cancer-killing cream (imiquimod) combined with targeted local radiation can shrink and control mycosis fungoides skin lesions. It may help people whose skin lymphoma has not responded to at least one prior standard treatment.
This early-phase study tests a spray solution (APR-TD011®) for people with early-stage mycosis fungoides and looks at how the bacteria on the skin change before and after treatment. It may help researchers understand whether the spray improves the skin environment that can affect this lymphoma.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.